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Asbestos causes lung ﬁbrosis known as asbestosis as well as cancers such as malignant mesothelioma and lung cancer. Asbestos is
a mineral silicate containing iron, magnesium, and calcium with a core of SiO2. The immunological eﬀect of silica, SiO2,i n v o l v e s
the dysregulation of autoimmunity because of the complications of autoimmune diseases found in silicosis. Asbestos can therefore
cause alteration of immunocompetent cells to result in a decline of tumor immunity. Additionally, due to its physical character-
istics,asbestosﬁbersremaininthelung,regionallymphnodes,andthepleuralcavity,particularlyattheopeningsitesoflymphatic
vessels. Asbestos can induce chronic inﬂammation in these areas due to the production of reactive oxygen/nitrogen species. As a
consequence, immunocompetent cells can have their cellular and molecular features altered by chronic and recurrent encounters
with asbestos ﬁbers, and there may be modiﬁcation by the surrounding inﬂammation, all of which eventually lead to decreased
tumorimmunity.Inthispaper,thebriefresultsofourinvestigationregardingreductionoftumorimmunityofimmunocompetent
cells exposed to asbestos in vitro are discussed, as are our ﬁndings concerned with an investigation of chronic inﬂammation and
analyses of peripheral blood samples derived from patients with pleural plaque and mesothelioma that have been exposed to
asbestos.
1.Introduction
Asbestos causes lung ﬁbrosis known as asbestosis, a few be-
nignpleuraldiseasessuchaspleuralplaqueandeﬀusion,and
malignant diseases such as mesothelioma and lung cancers
[1–5]. Furthermore, cancers in other organs such as the gas-
trointestinal tract, larynx, kidney, liver, pancreas, ovary, and
hematopoietic systems show ahigh prevalence in asbestos-
inhaled people [6–9]. This issue has been tackled as a major
medical and social problem throughout the world, especially
since asbestos is very useful in various industries for its min-
eral characteristics such as resistance to heat, cold, chemicals,
cheapness, easiness to obtain and weave, and so on [8, 9].
In Japan, the quantity of asbestos produced has increased
since the mid-1950s and reached a peak in 1974 (over
350,000z tons) [10–12]. The peak level of usage continued
until the late 1980s in construction, car, and other industries.
In the summer of 2005, Kubota Corporation, which mainly2 Journal of Biomedicine and Biotechnology
used asbestos to make water pipes in Amagasaki City, Hyogo
Prefecture, Japan, acknowledged the prevalence of asbestos-
related diseases among their workers, including several pa-
tients livingnearKubota’s asbestos-handling factoryin Ama-
gasaki City [10–12]. Citizens in Japan were suddenly made
awarethat asbestos causes malignancies in asbestos-handling
workers and in residents living near these factories. They
were informed that mesothelioma is diﬃcult to diagnose and
cure and were angered that workers and neighborhood resi-
dents had not been notiﬁed that these factories had been
handling this silent bomb, asbestos [10–12].
To reduce the anxieties of the Japanese people, epidemi-
ological analyses commenced regarding the Amagasaki area,
and clinical and basic research was conducted on the biolog-
ical eﬀects of asbestos and the early detection of mesotheli-
oma. It is in this context that the authors became involved in
the project “Comprehensive Approach on Asbestos-Related
Diseases”, supported by the “Special Coordination Funds for
Promoting Science and Technology” (headed by Dr. Takemi
Otsuki, Department of Hygiene, Kawasaki Medical School,
Kurashiki, Japan) from 2006 to 2010. In this project, a case
and clinical specimen registration system was established. A
feasibleclinicaltrialwasestablishedandinvolvedacombined
trimodality therapy using anticancer chemotherapy with
cisplatin and pemetrexed, followed by extrapleural pneumo-
nectomy and postoperative radiation therapy for early-stage
mesotheliomapatients[13,14].Furthermore,earlydetection
procedures were developed using serum or pleural eﬀusions
to measure soluble mesothelin-related peptide (SMRP) and
other markers such as osteopontin, vascular endothelial
growth Factor (VEGF), and angiopoietin-1 as well as proce-
dures for detection of circulating mesothelioma cells and cir-
culating epithelial cells using peripheral blood [15–19].
For the basic research, the project “Comprehensive Ap-
proach on Asbestos-Related Diseases” included three sub-
groups: (1) analyses of cellular and molecular characteristics
using mesothelioma cell lines, (2) an investigation of asbes-
tos-induced carcinogenesis using an animal model, and (3) a
study of the immunological eﬀects of silica/asbestos.
The basic research project (3) was performed by us, and
in this paper, we introduce our viewpoint that asbestos may
causealterationofimmunocompetentcellsresultinginchro-
nic inﬂammation as well as tumor development.
2. Immunological Effects of the Mineral
Silicateon Asbestos and Silica
Asbestos is a mineral silicate containing iron, magnesium,
and calcium, with a core of “Si” and “O” [6, 7]. Individuals
exposed to silica and asbestos develop lung ﬁbrosis known
as silicosis and asbestosis, respectively [1–5, 20]. Silicosis is
a form of occupational lung disease caused by inhalation of
crystalline silica dust, and is marked by inﬂammation and
scarring in the form of nodular lesions in the upper lobes of
the lungs [20]. However, asbestosis developsin patients who
inhale a relatively high dose of asbestos (compared with pa-
tientswithpleurallesionssuchasmesotheliomaandplaque).
In addition, the pathology of asbestosis diﬀers from that of
silicosis [1–5]. Asbestosis involves the scarring of lung tissue
(around the terminal bronchioles and alveolar ducts). There
aretwotypesofﬁbers:amphibole(thinandstraight)andser-
pentine (curved). The former are primarily responsible for
human disease as they are able to penetrate deeply into the
lungs. When such ﬁbers reach the alveoli in the lung, where
oxygen is transferred into the blood, the foreign bodies (asb-
estos ﬁbers) cause the activation of the lung’s local immune
system and provoke an inﬂammatory reaction [1–5]. This
inﬂammatory reaction can be described as chronic rather
than acute, slow ongoing activation of the immune system in
an attempt to eliminate the foreign ﬁbers. Macrophages pha-
gocytose the ﬁbers and stimulate ﬁbroblasts to deposit con-
nective tissue. Due to the natural resistance of asbestos ﬁbers
todigestion,themacrophagediesoﬀ,releasingcytokinesand
attracting further lung macrophages and ﬁbroblastic cells to
lay down ﬁbrous tissue, which eventually forms a ﬁbrous
mass [21, 22]. The result is interstitial ﬁbrosis. The ﬁbrotic
scartissuecausesalveolarwallstothicken,whichreducesela-
sticityandgasdiﬀusion,reducingoxygentransfertobloodas
well as the removing of carbon dioxide.
Furthermore, the complications in silicosis and in people
who have inhaled asbestos are also diﬀerent. Patients with
silicosis often present with complications involving autoim-
mune diseases such as rheumatoid arthritis (known as Cap-
lan’s syndrome) [23–25], systemic sclerosis [26, 27], systemic
lupus erythematosus [28, 29], and antineutrophil cytoplas-
mic antibody (ANCA)-related vasculitis/nephritis [30–32].
Although these have been considered adjuvant eﬀects of sil-
ica,wehaveassumedthatsilicamayinﬂuencecirculatingim-
munocompetent cells, particularly T lymphocytes, and have
reported that silica can activate CD4+25+FoxP3 (forkhead
box P3) + regulatory T cells (Treg) and responder T cells
(Tresp) [33–38]. These activations induce overexpression of
CD95/Fas in Treg, resulting in early loss and contamination
of activated Tresp, which express CD25 as the marker for
activation into a peripheral CD4+25+ subpopulation of T
cells.Thesephenomenaseemtoinducereducedregulationof
autoimmunity [37, 38]. Regarding silica-induced ﬁbrosis
(lung and skin), the idea proposed previously [27] is that sil-
ica aﬀect alveolar macrophages, endothelial cells, and ﬁbro-
blasts to modify cytokine production and disturbance of col-
lagensynthesisanddegradation,subsequentlyformingﬁbro-
sisoflungandskinlesion.Inaddition,ourﬁndingssuggested
that silica may inﬂuence and alter circulating lymphocytes to
disturb autoimmune tolerance [37, 38].
On the other hand, a consideration of the complications
of asbestos exposure indicates that the development of can-
cers is the most important aspect [1–5]. As silica can aﬀect
immunocompetent cells, asbestos may possess a similar in-
ﬂuence on various immune cells, and the results should be
the reduction of tumor immunity. As mentioned above, in
addition to lung cancer and mesothelioma, there may be a
relatively high prevalence of other cancers among asbestos-
inhaled patients [6, 7].
Wehavereportedthatthenaturalkiller(NK)celllineand
freshly isolated NK cells derived from healthy donors (HDs)
exposed to asbestos (chrysotile) for a long period (more than
half a year in vitro for the cell line and approximately twoJournal of Biomedicine and Biotechnology 3
weeks for the fresh NK cells) showed a reduction of cytotox-
icity with decreased expression of their activating receptors,
such as NKG2D and 2B4 in the cell line and NKp46 in the
fresh NK cells [39]. The NK cell line exposed to asbestos also
showed suppressed signaling such as extracellular signal-
regulated kinas (ERK) 1/2 in the mitogen-activated protein
kinase (MAPK) cascade from activating receptors and also
producting of granzyme and perforin [40, 41]. At present,
the eﬀects of chrysotile on CD8+ cytotoxic T lymphocytes
(CTL) are also being analyzed, and ﬁndings show reduction
of diﬀerentiation from na¨ ıve CTL to eﬀector/memory CTL
and proliferation [42].
3. ChronicInﬂammation andDevelopment
of Mesothelioma
Inhaled asbestos is usually handled by alveolar macrophages.
Recently, the role of a NOD-like receptor family, the pyrin
domain containing 3 (NLRP3) (NACHT, LRR, and PYD do-
mains-containing protein 3; Nalp3) inﬂammasome, has
received attention regarding the handling of these foreign
bodies as well as various crystalline substances such as uric
acid and cholesterol crystalline causing atherosclerosis [43–
47]. The following cellular and molecular events then occur.
(1) Capture of silica/asbestos by macrophages and entrap-
ment within lysosomes. (2) Activation of NLRP3 inﬂamma-
sometocleaveprocaspase1toanactiveform.(3)Cleavageof
prointerleukin (IL)-1β to an active form for release to form
ﬁbrotic nodules. (4) Production of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) in the macropha-
ges. (5) Induction of cellular and tissue damage due to the
production of ROS and RNS. (6) Apoptosis of the alveolar
macrophages. (7) Production of various cytokines/chemo-
kines such as IL-1β tumor necrosis factor (TNF)-α,m a c r o -
phage inﬂammatory protein (MIP)-1/2, monocyte-chemo-
attractant protein-1, and IL-8 to cause chronic inﬂammation
andproliferationofcollagenicﬁbers.(8)Releaseofsilicapar-
ticles and asbestos ﬁbers from alveolar macrophages and the
repetition of similar cellular reactions described above by
newly recognized nearby macrophages. (9) Transfer of silica
particles and (partially cleaved) asbestos ﬁbers to regional
lymph nodes. (10) As these cellular and molecular reactions
are continuously repeated, pulmonary ﬁbrosis will appear
gradually and progressively [48, 49].
As a result of these cellular and molecular events, cleaved
asbestos ﬁbers will accumulate in regional lymphonodes, the
distal end of the alveolus, and the pleural cavity, particularly
at the opening of lymphatic vessels (Figure 1)[ 1–5]. Cir-
culating and local immunocompetent cells may encounter
asbestos ﬁbers repeatedly, recurrently, and continuously.
Asbestos, particularly amphibole in the form of crocido-
lite and amosite, includes iron and is considered responsible
for the production of reactive oxygen and nitrogen species
(ROS and RNS) that may cause DNA damage to nearby
cells and induce the development of cancers [50–52]. In
addition, these ROS and RNS may develop local chronic
inﬂammation. It has been thought that chronic inﬂamma-
tion contributes to a substantial part of environmental car-
cinogenesis [53–55]. Various infectious diseases and physi-
cal, chemical, and immunological factors participate in in-
ﬂammation-related carcinogenesis [50–55]. For example,
hepatocellular carcinoma, cervical cancer of uterine, and
bladder cancer are known to be caused by infection of hepa-
titisCvirus,humanpapillomavirus(HPV),andSchistosoma
haematobium, respectively. In addition, Helicobacter pylori
infection causes gastric cancer, extranodal marginal zone
lymphoma of mucosa-associated lymphoid tissue type
(MALT lymphoma), and diﬀuse large B-cell lymphoma. Re-
garding incidences of these diseases, WHO reported about
HepatitisCvirus[56].Asmanyas2to4millionpersonsmay
bechronicallyinfectedintheUnitedStates,5to10million in
Europe,andabout12millioninIndia,andmostdonotknow
that they are infected. About 150,000 new cases occur an-
nually in the USA and in western Europe and about 350,000
in Japan. Of these, about 25% are symptomatic, but 60 to
80% may progress to chronic liver disease, and 20% of these
develop cirrhosis. About 5%–7% of patients may ultimately
die of the consequences of the infection. In addition, HPV
causes cervical cancer which is the second most common
cancer in women worldwide. In 2008, there were an estimat-
ed 529,000 new cases and 274,00 deaths due to cervical can-
cer [57]. It was reported that 8-nitroguanine was formed at
sites of carcinogenesis in animal models and patients with
various cancer-prone infectious and inﬂammatory diseases,
caused by parasites, viruses, and asbestos exposure. In
asbestos-exposed mice, 8-nitroguanine was formed in bron-
chial epithelial cells, and it is noteworthy that crocidolite
inducedsigniﬁcantlymoreintense8-nitroguanineformation
than chrysotile, ﬁndings that are inconsistent with their res-
pective carcinogenic potentials [58].
Fromtheabove-mentionedbasicresearch(2)concerning
“investigation of asbestos-induced carcinogenesis using an
animal model” in the “Comprehensive Approach on Asb-
estos-Related Diseases” project, the importance of iron is
supposed even in the development of mesothelioma caused
by iron-free chrysotile because of its easy binding to hemo-
globin and the induced hemolysis [59–61]. Immunocompe-
tentcellsmayshowsomealterationascharacteristicsofchro-
nic inﬂammation and features involving reduced tumor im-
munity.
Fromthisviewpoint,eventhoughwedonotobservecell-
ular and molecular changes for immunocompetent cells, we
reported interesting ﬁndings regarding the reduction of
tumor immunity in T cells. We then introduce the ﬁndings
concerning reduction of CXC chemokine receptor (CXCR) 3
and interferon (IFN)-γ with the activated potential expres-
sion of IL-6.
4. Chemokine Receptor CXCR3 Expression and
Its Relation To Interferon (IFN)-γ andIL-6
Similar to analyses of NK cells, we adopted a human T-cell
line,MT-2,asthechronicandcontinuousexposuremodelof
T cells. Although the altered features of continuously expos-
ed (to chrysotile) sublines (we established six sublines4 Journal of Biomedicine and Biotechnology
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Figure 1: Localization of inhaled asbestos ﬁbers in the lung, pleural cavity, and regional lymphonodes. Chronic and recurrent encounters
between circulating immunocompetent cells and these moored asbestos ﬁbers causing the long-term alteration of these cells.
independently exposed to chrysotile) of MT-2 were reported
previously [62–64], one of the interesting molecular changes
regarding tumor immunity is the reduction of CXCR3 ex-
pression and IFN-γ production [65–68]. CXCR3 is thought
to be important for inﬂammation, since CXCR3 is known as
the receptor for CXCL9, 10, and 11 which induce inﬂamma-
tion. In addition, CXCR3 expressing T cells in the tumor-
localized region recruit IFN-γ-producing cells to kill the
tumor cells.
Results using the MT-2 cell line model, as shown in the
left upper panel of Figure 2, indicated that continuously ex-
posed sublines of MT-2 showed reduced CXCR3 expression
on their surface and mRNA expression levels, with reduced
production and expression of IFN-γ. Production of the Th1
type CXCR3 ligand CXCL10/IP10 was also signiﬁcantly re-
duced in sublines compared with the original line. In addi-
tion, another Th1-type chemokine, CCL4/MIP-1β mRNA,
was also expressed at low levels in all six sublines compared
with the MT-2 original line as previously reported [69, 70].
However, CCR5, the Th1-type receptor for CCL4/MIP-1β,
was not reduced signiﬁcantly through mRNA expression in
MT-2Rsts cells. These results indicated that continuous ex-
posure of MT-2 original cells to asbestos altered the ex-
pression of Th1-related chemokines (CXCL10/IP10 and
CCL4/MIP-1β) and chemokine receptors (CXCR3) [69, 70].
Similar to analyses regarding the eﬀects of asbestos on
NK cells, we then tried to determine whether freshly isolated
human peripheral CD4+ T cells show a similar alteration
ex vivo when proliferation is maintained by IL-2-containing
medium in the presence of chrysotile as shown in the left
lower panel of Figure 2 [69, 70]. After several weeks of co-
culture supplemented with IL-2 in the presence or absence of
chrysotile, cell surface CXCR3 expression decreased in a
dose-dependent manner. Thus, we examined cell surface ex-
pression of CXCR3 and CCR5 in CD4+ T cells derived from
six healthy donors, since both receptors are preferentially ex-
pressedinTh1/eﬀectorTcells.TheexpressionofCXCR3was
signiﬁcantly reduced following exposure to 10μg/mL of
chrysotile for 28 days, although this diﬀerence seemed to
depend on one case in which the expression decreased re-
markably [69, 70]. Even if the culture conditions for the
CD4+ T cells was limited to a period of around four weeks,
four of the six HDs showed a decrease of CXCR3 expression
to various degrees, and it might be concluded that asbestos
exposure potentiates reduction of CXCR3 expression in
CD4+ T cells. These results indicated that CXCR3 expression
might be speciﬁcally reduced by asbestos exposure. In addi-
tion, these experiments revealed decreased IFN-γ expression
and production when CD4+ T cells from HDs were cultured
with chrysotile for 28 days [69, 70].
Finally, analyses of changes in surface CXCR3 expression
on freshly isolated CD4+ T cells from asbestos-exposed pa-
tients such as those with pleural plaque (PP) or malignant
mesothelioma (MM) were compared with those from HDs.
In addition, IFN-γ and IL-6 expression of CD4+ T cells from
these patients and HDs was measured with stimulation using
anti-CD3/CD28 antibodies with IL-2 [69, 70]. As sum-
marized in the right panel of Figure 2, CXCR3 expression
wasreducedin CD4+ Tcellsfromasbestos-exposed patients.
AcomparisonofPPandMMpatientsshowedthattheexpre-
ssion level of CXCR3 on CD4+ T cells from MM was de-
creased, although the diﬀerence was not statistically signiﬁ-
cant. Moreover, althoughIFN-γ expression was only reduced
in stimulated CD4+ T cells from MM patients and not in
those with PP, IL-6 expression was gradually enhanced in
HDs and to a lesser extent in PP, followed by MM. As we
reported previously, the plasma level of IL-6 was signiﬁcantly
higher in MM compared to HDs, PP, and silicosis [71].Journal of Biomedicine and Biotechnology 5
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in-ﬂammation and reduced tumor immunity.
Although this may depend on the tumor-producing IL-6
[72–74], our ﬁndings indicated that part of the increased
IL-6 maybe produced by T cellswith altered potentials to ex-
press cytokines due to continuous exposure to asbestos.
Furthermore, IL-6 is an interleukin that acts as a proinﬂam-
matory and anti-inﬂammatory cytokine. It is secreted by T
cells and macrophages to stimulate an immune response,
for example, during infection and after trauma, especially
in the caseof burns or other tissue damage leading toinﬂam-
mation [75–78]. For these reasons, it can be assumed that
immunocompetent cells possess cellular characteristics of
chronic inﬂammatory alterations during continuous expo-
sure to asbestos, and they then proceed to result in the
reduction of tumor immunity as shown in Figure 3.I n
addition, the supposed diﬀerence of immunological eﬀects
between silica and asbestos is shown in Figure 4.H o w e v e r ,
although there is insuﬃcient evidence for all of these
sequential modiﬁcations of immunocompetent cells,6 Journal of Biomedicine and Biotechnology
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disturb the autoimmunity, and asbestos may cause reduction of tumor immunity via forming chronic inﬂammation.
an investigation of their long-term alteration may lead to the
development of preventive tools for asbestos-induced mali-
gnancies. For example, it may be possible to ﬁnd some physi-
ologically active substances in the plants or microorganisms
to modify or recover the altered function of immunocom-
petent cells to reconstitute the tumor immunity in asbestos-
exposed people, and discriminate iron from bodies exposed
to asbesots.
5. Conclusion
As shown in Figure 3, the carcinogenic activity of asbestos
encompasses the following phenomena: (1) DNA damage
caused by ROS/RNS production due to the iron presentin
asbestos ﬁbers, (2) chromosome tangling to result in DNA
damage due to the physical features of asbestos ﬁbers, and
(3) adsorption of various carcinogensaround the asbestos
ﬁbers [59–61]. In addition, the molecular events regarding
carcinogenesis found in mesothelioma cells include (1)
homogenous deletion of p16INK4a/p19ARF found in more
than 90% of cases, (2) inactivation of neuroﬁbromatosis 2
(NF2)/Merlin found in approximately half of the cases, (3)
inactivation of the serine/threonine-protein kinase (LATS2)
gene in approximately one-third of mesothelioma cell lines
and representinga candidate for a novel tumor suppressor in
MM, and (4) transcription factor, Yes-associated protein
(YAP) involved in the NF2/Merlin-hippo signaling pathway
and constitutively dephosphorylated by LATS, and usually
acting as an oncogene to bind with the TEAD transcription
factor to enhance the cell cycle and resistance to apoptosis
[79–81].
Asbestos ﬁbers and the cellular and molecular character-
isticsofmesotheliomacellsmayleadtothegradualalteration
of immunocompetent cells and subsequent development of
chronic inﬂammation and later reduction of tumor immu-
nity. Investigation of the progression of modiﬁcation in im-
munocompetent cells caused by exposure to asbestos may
lead to the development of novel methods for the prevention
of mesothelioma and other asbestos-related cancers.
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